ImmuPharma plc

IMM.L · LSE
Analyze with AI
6/30/2025
3/31/2025
12/31/2024
9/30/2024
Revenue£0£0£0£0
% Growth
Cost of Goods Sold£0£0£0£0
Gross Profit-£0£0-£0£0
% Margin
R&D Expenses£0£0£0£0
G&A Expenses£0£0£0£0
SG&A Expenses£0£0£0£0
Sales & Mktg Exp.£0£0£0£0
Other Operating Expenses-£0-£0£1£0
Operating Expenses£1£1£1£1
Operating Income-£1-£1-£2-£1
% Margin
Other Income/Exp. Net-£1-£0-£1-£0
Pre-Tax Income-£2-£1-£2-£1
Tax Expense-£0£0-£0-£0
Net Income-£1-£1-£1-£1
% Margin
EPS-0.002-0.002-0.003-0.003
% Growth0%24%0%
EPS Diluted-0.002-0.002-0.003-0.003
Weighted Avg Shares Out480480416411
Weighted Avg Shares Out Dil480480416416
Supplemental Information
Interest Income£0£0-£0£0
Interest Expense£1£0£0£0
Depreciation & Amortization£0£0£0£0
EBITDA-£1-£1-£1-£1
% Margin
ImmuPharma plc (IMM.L) Financial Statements & Key Stats | AlphaPilot